Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-1473 (Izencitinib) Induction Therapy in Crohn's Disease
NCT03635112Phase 2Terminated
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Nov 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 2 trial of izencitinib in Crohn's disease, sponsored by Theravance Biopharma, Inc.. Started Nov 2018; status: terminated.
02
Drugs
izencitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03635112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03635112.